185 related articles for article (PubMed ID: 3157567)
21. Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
Mini E; Novelli A; Mazzei T; Periti P
Eur J Clin Microbiol Infect Dis; 1989 Mar; 8(3):256-60. PubMed ID: 2523807
[TBL] [Abstract][Full Text] [Related]
22. In vitro evaluation of teicoplanin and other antimicrobials against streptococci group D bacteria.
Breyer S; Georgopoulos A; Graninger W
Drugs Exp Clin Res; 1987; 13(8):479-81. PubMed ID: 2962843
[TBL] [Abstract][Full Text] [Related]
23. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin.
Greenwood D; Bidgood K; Turner M
J Antimicrob Chemother; 1987 Aug; 20(2):155-64. PubMed ID: 2959642
[TBL] [Abstract][Full Text] [Related]
24. In vitro sensitivity of erythromycin-resistant strains of staphylococci and enterococci to vancomycin and novobiocin.
SCHNEIERSON SS; AMSTERDAM D
Antibiot Chemother (Northfield); 1957 May; 7(5):251-4. PubMed ID: 24544426
[No Abstract] [Full Text] [Related]
25. In vitro interactions between teicoplanin and other antibiotics against enterococci and staphylococci.
Debbia E; Pesce A; Schito GC
J Hosp Infect; 1986 Mar; 7 Suppl A():73-7. PubMed ID: 2871100
[TBL] [Abstract][Full Text] [Related]
26. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility of gram positive cocci to teicoplanin. Three year survey (1984-1986) at Perugia University.
Pasticci MB; Baldelli F; Moretti A; Menichetti F; Pauluzzi S
Boll Ist Sieroter Milan; 1989; 68(1):5-6. PubMed ID: 2535245
[TBL] [Abstract][Full Text] [Related]
28. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.
O'Neill AJ; Cove JH; Chopra I
J Antimicrob Chemother; 2001 May; 47(5):647-50. PubMed ID: 11328777
[TBL] [Abstract][Full Text] [Related]
29. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
30. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
Shibl AM; Ishag AH; Durgham SM
APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
[TBL] [Abstract][Full Text] [Related]
31. Comparative post-antibiotic effect of five antibiotics against ten aerobic gram-positive cocci.
Drabu YJ; Blakemore PH
Drugs Exp Clin Res; 1990; 16(11):557-63. PubMed ID: 2151661
[TBL] [Abstract][Full Text] [Related]
32. In-vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin or tobramycin against coagulase-negative staphylococci.
Watanakunakorn C
J Antimicrob Chemother; 1987 Apr; 19(4):439-43. PubMed ID: 2953706
[TBL] [Abstract][Full Text] [Related]
33. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium.
Leclercq R; Derlot E; Weber M; Duval J; Courvalin P
Antimicrob Agents Chemother; 1989 Jan; 33(1):10-5. PubMed ID: 2523687
[TBL] [Abstract][Full Text] [Related]
34. Comparative in-vitro activities of teicoplanin, vancomycin, coumermycin and ciprofloxacin, alone and in combination with rifampicin or LM 427, against Staphylococcus aureus.
Van der Auwera P; Joly P
J Antimicrob Chemother; 1987 Mar; 19(3):313-20. PubMed ID: 3032884
[TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
[TBL] [Abstract][Full Text] [Related]
36. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin.
Cooper MA; Jin YF; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1990 Aug; 26(2):203-7. PubMed ID: 2145256
[TBL] [Abstract][Full Text] [Related]
37. Novobiocin and rifampicin in combination against methicillin-resistant Staphylococcus aureus: an in-vitro comparison with vancomycin plus rifampicin.
Walsh TJ; Auger F; Tatem BA; Hansen SL; Standiford HC
J Antimicrob Chemother; 1986 Jan; 17(1):75-82. PubMed ID: 3633267
[TBL] [Abstract][Full Text] [Related]
38. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
40. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
Mushtaq S; Warner M; Johnson AP; Livermore DM
J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
